David Morris, MD

Learn how PSMA PET sharpens staging, guides Pluvicto dosing, and avoids false-positive traps—changing treatment for advanced prostate cancer.

Clinicians weigh PSMA PET’s strengths, limits, and tracer differences, plus when to scan after recurrence to guide salvage prostate cancer therapy.

Learn how FDA-approved PSMA PET tracers differ in prostate cancer staging and recurrence, including urinary uptake nuances that may affect post-prostatectomy detection.

PSMA PET reshapes advanced prostate cancer care, guiding Pluvicto use and tracking response with emerging PCWG4 criteria.

How teams use PSMA PET to stage prostate cancer: who orders, who reads, and how tumor boards refine treatment when findings conflict.

Learn how PSMA PET reshapes prostate cancer staging, outperforms CT and bone scans, and finds recurrence even at very low PSA.